YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Economic Value of Platelet Glycoprotein IIb/IIIA Receptor Blocker (Abciximab) for Percutaneous Coronary Intervention

PCI시술시 혈소판 당단백 GP IIb/IIIA 억제제(Abciximab) 투여의 경제적 가치

  • Kim, Jin-hyun (College of Nursing, Seoul National University) ;
  • Shin, Sang-Jin (School of Public Health, Seoul National University) ;
  • Kim, Eun-Ju (School of Public Health, Seoul National University) ;
  • Lee, Young-Hee (School of Public Health, Seoul National University)
  • 김진현 (서울대학교 간호대학) ;
  • 신상진 (서울대학교 보건대학원) ;
  • 김은주 (서울대학교 보건대학원) ;
  • 이영희 (서울대학교 보건대학원)
  • Published : 2007.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study was performed to analyse the economic value of abciximab which is used in PCI to prevent high-risk patients with ischemic complications. The effectiveness of abciximab was extracted from published clinical trials by search-ing CCIS, and the direct medical costs relevant to using abciximab were estimated from the NHI claims database. The results in terms of cost per life-year gained (LYG) and cost per QALY gained showed that abciximab was cost-effective enough to deserve its cost. Social net benefit resulting from abciximab in PCI was estimated to be 60-70 billion Won per year.

Keywords

References

  1. Ellis, S. G., Roubin, G. S., King, S. B., 3rd, Douglas, J. S., Jr., Weintraub, W. S., Thomas, R. G. and Cox, W. R. : Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 77, 2 (1988) https://doi.org/10.1161/01.CIR.77.5.988
  2. Lincoff, A. M., Popma, J. J., Ellis, S. G., Hacker, J. A. and Topol, E. J. : Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J. Am. Coll. Cardiol. 19, 5 (1992)
  3. Tenaglia, A. N., Fortin, D. F., Califf, R. M., Frid, D. J., Nelson, C. L., Gardner, L., Miller, M., Navetta, F. I., Smith, J. E., Tcheng, J. E., et al. : Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. J. Am. Coll. Cardiol. 24, 4 (1994)
  4. Topol, E. J., Califf, R. M., Weisman, H. F., Ellis, S. G., Tcheng, J. E., Worley, S., Ivanhoe, R., George, B. S., Fintel, D., Weston, M., et al. : Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 343, 8902 (1994)
  5. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. The New England Journal of Medicine 336, 24 (1997)
  6. The CAPTURE Study: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349, 9063 (1997)
  7. 박우석, 정명호, 김남호, 안영근, 배열, 길광채, 조정관, 박종춘, 강정채 : 고위험군 환자의 Abciximab(ReoPro)을 사용하며 성공 적으로 시행한 관상동맥 중재술 1예. 대한중환자의학회지 13, (1998)
  8. 정해억, 승기배, 장정원, 김용주, 임상현, 김태균, 장기욱, 임효영, 정욱성, 김종진, 채장성, 김재형, 홍순조, 최규보 : 급성 심근경색증에 대한 일차 관상동맥중재술 중 투여한 압시씨맵(Abciximab) 의 관상동맥 혈류개선효과에 대한 분석-교정 TIMI Frame계산법을 이용하여. Korean Circulation 30, 7 (2000)
  9. 김원, 정명호, 홍영준, 이승현, 박우석, 김주한, 김인수, 최명자, 안영근, 조정관, 박종춘, 조동련, 김훈, 강정채 : 혈소판 당단백 IIb/IIIa 수용체 차단제(Abciximab: ReoPro)부착 관상동맥 스텐트의 장기 임상결과. 대한내과학회지 65, 6 (2003)
  10. 김원, 정명호, 홍영준, 박형욱, 이민구, 정선영, 김인수, 김계훈, 윤경호, 강동구, 홍서나, 임상엽, 이상현, 이연상, 김주한, 안영근, 조정관, 박종춘, 김훈, 조동련, 강정채 : 급성 심근경색증 환자에 게 혈소판 당단백 IIb/IIIa 수용체 차단제(AbciximabL ReoPro) 부착 관상동맥 스텐트의 장기임상결과. Korean Circulation 34, 11 (2004)
  11. 권운정, 이태홍, 이병희, 김동현, 김학진, 김석, 김창원, 추기석, 문태용 : 두개강 내 동맥 스텐트 삽입시 발생한 급성 스텐트 내 혈전에 대한 Abciximab 동맥 내 주입치료의 유용성. 대한영상의학회지 51, (2004)
  12. The EPIC Investigation: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The New England Journal of Medicine 330, 14 (1994)
  13. Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E., Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D. P., Anderson, K. M. and Califf, R. M. : Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/ IIIa Inhibition for Prevention of Ischemic Complication. Jama 278, 6 (1997)
  14. Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J., Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C., Cabot, C. F., Anderson, K. M., Weisman, H. F. and Topol, E. J. : Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial.Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 99, 15 (1999)
  15. Lincoff, A. M., Califf, R. M., Moliterno, D. J., Ellis, S. G., Ducas, J., Kramer, J. H., Kleiman, N. S., Cohen, E. A., Booth, J. E., Sapp, S. K., Cabot, C. F. and Topol, E. J. : Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. The New England Journal of Medicine 341, 5 (1999)
  16. Brener, S. J., Barr, L. A., Burchenal, J. E., Katz, S., George, B. S., Jones, A. A., Cohen, E. D., Gainey, P. C., White, H. J., Cheek, H. B., Moses, J. W., Moliterno, D. J., Effron, M. B. and Topol, E. J.: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98, 8 (1998)
  17. Stone, G. W., Grines, C. L., Cox, D. A., Garcia, E., Tcheng, J. E., Griffin, J. J., Guagliumi, G., Stuckey, T., Turco, M., Carroll, J. D., Rutherford, B. D. and Lansky, A. J. : Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. The New England Journal of Medicine 346, 13 (2002) https://doi.org/10.1056/NEJM200201033460102
  18. Montalescot, G., Barragan, P., Wittenberg, O., Ecollan, P., Elhadad, S., Villain, P., Boulenc, J. M., Morice, M. C., Maillard, L., Pansieri, M., Choussat, R. and Pinton, P. : Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. The New England Journal of Medicine 344, 25 (2001)
  19. Weintraub, W. S., Mahoney, E. M., Zhang, Z., Chu, H., Hutton, J., Buxton, M., Booth, J., Nugara, F., Stables, R. H., Dooley, P., Collinson, J., Stuteville, M., Delahunty, N., Wright, A., Flather, M. D. and Cock, E. De : One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Heart 90, (2004)
  20. Stinnett, A. A., Mittleman, M. A., Weinstein, M. C., Karen, M. K., Cohen, D. J., Williams, L. W., Goldman, P. A., Staiger, D. O., Hunink, M. G. M., Tsevat, J., Tosteson, A. N. A., Goldman, L. : The Cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. In: Gold, M. R., Stegel, J. E., Russell, L. B., Weinstein, M. C., eds. Cost- Effectiveness in Health and Medicine. New york: Oxford University Press, 349 (1996)
  21. Aristides, M., Gliksman, M., Rajan, N. and Davey, P. : Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Heart 79, 1 (1998)
  22. Oh, P. I., Cohen, E. A., Mittmann, N. and Seung, S. J. : The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both? Can. J. Clin. Pharmacol. 11, 2 (2004)
  23. Topol, E. J., Mark, D. B., Lincoff, A. M., Cohen, E., Burton, J., Kleiman, N., Talley, D., Sapp, S., Booth, J., Cabot, C. F., Anderson, K. M. and Califf, R. M. : Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 354, 9195 (1999) https://doi.org/10.1016/S0140-6736(99)02080-2
  24. Kereiakes, D. J., Obenchain, R. L., Barber, B. L., Smith, A., McDonald, M., Broderick, T. M., Runyon, J. P., Shimshak, T. M., Schneider, J. F., Hattemer, C. R., Roth, E. M., Whang, D. D., Cocks, D. and Abbottsmith, C. W. : Abciximab provides cost-effective survival advantage in high-volume interventional practice. Am. Heart. J. 140, 4 (2000)
  25. Young, J. J. and Kereiakes, D. J. : Abciximab: cost-effective survival advantage in clinical trials and clinical practice. Am. Heart. J. 140, 6 Suppl (2000)
  26. Hillegass, W. B., Newman, A. R. and Raco, D. L. : Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications. Pharmacoeconomics 19, 1 (2001)
  27. Califf, R. M. : Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses? Stat. Med. 21, 19 (2002)
  28. McCollam, P. L., Foster, D. A. and Riesmeyer, J. S. : Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am. J. Health Syst. Pharm. 60, 12 (2003)